List of Excipients in Branded Drug INVIRASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	INVIRASE	saquinavir mesylate	0004-0244	CELLULOSE, MICROCRYSTALLINE
Genentech Inc	INVIRASE	saquinavir mesylate	0004-0244	CROSCARMELLOSE SODIUM
Genentech Inc	INVIRASE	saquinavir mesylate	0004-0244	FERRIC OXIDE RED
Genentech Inc	INVIRASE	saquinavir mesylate	0004-0244	FERRIC OXIDE YELLOW
Genentech Inc	INVIRASE	saquinavir mesylate	0004-0244	HYPROMELLOSE
Genentech Inc	INVIRASE	saquinavir mesylate	0004-0244	LACTOSE MONOHYDRATE

INVIRASE (Saquinavir) Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Invirase contains saquinavir mesylate, an older HIV-1 protease inhibitor whose commercial value is limited by poor oral bioavailability, extensive CYP3A4 metabolism, and competition from newer antiretroviral regimens. The strongest excipient opportunities are enabling formulations that improve exposure, reduce food dependence, support lower-dose administration, or create differentiated liquid and fixed-dose products. Direct branded-product opportunities are weak because original small-molecule exclusivity has expired and saquinavir is no longer a preferred component of most HIV treatment regimens.[1][2]

What is Invirase and how do its formulation properties affect excipient selection?

Invirase is the hard-gelatin capsule and film-coated tablet formulation of saquinavir mesylate. The drug is administered with ritonavir, which inhibits CYP3A-mediated metabolism and increases saquinavir exposure.[1]

Key formulation constraints

Attribute	Commercial implication
Active ingredient	Saquinavir mesylate
Drug class	HIV-1 protease inhibitor
Primary dosage forms	200 mg capsule and 500 mg tablet
Main pharmacokinetic issue	Low and variable oral bioavailability
Metabolic liability	Extensive CYP3A4 metabolism
Administration requirement	Use with ritonavir; administration with food is specified
Main formulation risk	Inadequate dissolution and exposure variability
Regulatory pathway for a new small-molecule product	ANDA, 505(b)(2), or new NDA depending on claims

Saquinavir has low aqueous solubility and a substantial first-pass effect. Its absorption is sensitive to formulation, food, gastric conditions, and metabolic inhibition. An excipient program therefore has to address both dissolution and systemic exposure. Improving tablet hardness or manufacturing efficiency alone would have limited commercial value unless the product also improves pharmacokinetic performance.

What excipients are used in Invirase capsules and tablets?

The FDA labeling identifies conventional solid-dose excipients in Invirase. The precise composition differs between the 200 mg capsule and 500 mg tablet.[1]

Invirase capsule excipients

The capsule formulation uses excipients associated with direct compression or capsule filling, including:

• Lactose monohydrate
• Microcrystalline cellulose
• Povidone
• Talc
• Magnesium stearate
• Gelatin capsule shell components
• Titanium dioxide and iron oxide colorants

Invirase tablet excipients

The 500 mg film-coated tablet uses a larger compression and coating system, including:

• Lactose monohydrate
• Microcrystalline cellulose
• Povidone
• Crospovidone
• Colloidal silicon dioxide
• Magnesium stearate
• Hypromellose
• Talc
• Titanium dioxide
• Iron oxide colorants

These ingredients are commercially available and do not, by themselves, create a meaningful barrier to generic development. Their main value is manufacturing functionality: diluency, binding, disintegration, flow, lubrication, and coating performance.

Which excipient strategies can improve saquinavir performance?

1. Amorphous solid dispersions

An amorphous solid dispersion could improve apparent solubility and dissolution by dispersing saquinavir in a polymeric carrier. Candidate polymers may include hypromellose-based systems, hypromellose acetate succinate, polyvinylpyrrolidone, or copovidone.

The commercial value would depend on demonstrated improvement in:

• Dissolution under biorelevant conditions
• Exposure at lower dose
• Reproducibility across fed and fasted states
• Physical stability during storage
• Compatibility with ritonavir administration

The main technical risk is recrystallization. Saquinavir’s relatively high drug loading requirement may also make an amorphous system difficult to stabilize without increasing tablet size.

2. Lipid-based formulations

Lipid-based systems are technically attractive for poorly soluble, highly lipophilic drugs. Options include:

• Self-emulsifying drug delivery systems
• Self-microemulsifying drug delivery systems
• Medium-chain triglycerides
• Long-chain glycerides
• Nonionic surfactants
• Solubilizing co-solvents

A lipid formulation could reduce dissolution dependence and potentially improve exposure. The challenge is that saquinavir is already administered with ritonavir and food, so the incremental benefit must be large enough to justify a new dosage form, new stability work, and potentially new clinical studies.

Lipid excipients also require careful control of gastrointestinal tolerability, capsule-shell compatibility, oxidation, and dose-volume constraints.

3. Nanocrystals and particle-size engineering

Nanocrystal technology could increase dissolution rate without relying on a large polymer load. Stabilizers such as surfactants or hydrophilic polymers may help maintain dispersion.

This approach may be suitable for:

• Smaller tablets
• Rapid-release products
• Lower-dose boosted regimens
• Pediatric or geriatric dosage forms

Nanocrystals do not automatically overcome first-pass metabolism. They improve dissolution, but the exposure gain may be limited if metabolism remains the dominant constraint.

4. Cyclodextrin complexes

Cyclodextrins may improve apparent solubility and support liquid or orally disintegrating formulations. Their use is more commercially plausible in a pediatric or specialty formulation than in a conventional adult tablet.

The main constraints are:

• High excipient-to-drug ratios
• Dose-volume burden
• Cost
• Gastrointestinal tolerability
• Regulatory justification for chronic administration

5. Taste-masked liquid and multiparticulate systems

An oral liquid, powder for suspension, or taste-masked multiparticulate product could address swallowing difficulty and pediatric administration. Potential technologies include:

• Polymer-coated drug particles
• Ion-exchange resins
• Lipid microparticles
• Drug-loaded granules
• Flavor and sweetener systems
• Ready-to-use or reconstituted suspensions

A pediatric formulation would require more than taste masking. It would need acceptable dose flexibility, microbial control, chemical stability, dosing-device accuracy, and a manageable excipient profile for chronic use.

What formulations are protected by Invirase patents?

The original saquinavir compound, formulation, and use patents are old relative to current pharmaceutical patent terms. The commercially relevant exclusivity period for the original product has expired. FDA’s Orange Book is the operative source for current listed patents and regulatory exclusivity, but excipient compositions are not generally protected through Orange Book listing unless they fall within a qualifying drug-product patent.[3]

Patent protection by product category

Product element	Current strategic relevance
Saquinavir active ingredient	Original compound protection has expired
Conventional capsule formulation	Limited protection; readily reproducible excipient system
Conventional 500 mg tablet	Limited protection absent a live formulation patent
Ritonavir-boosted administration	Method-of-use concepts are old and commercially crowded
Novel lipid or amorphous formulation	Potential new patent subject matter
Pediatric liquid or multiparticulate formulation	Potential formulation and use claims
Manufacturing process	Possible process protection if a non-obvious process is developed
Excipient substitution	Usually weak unless linked to a measurable performance advantage

A new patent position would need to claim a specific formulation architecture, manufacturing process, release profile, stability result, or pharmacokinetic advantage. Broad claims covering ordinary lactose, cellulose, povidone, crospovidone, or magnesium stearate combinations would face substantial validity and obviousness risk.

When does Invirase lose exclusivity, and what is the generic entry risk?

Invirase has already lost the practical protection associated with its original regulatory exclusivity and patent estate. The product is a small molecule, so competitive entry would occur through an ANDA rather than a biosimilar application.[1][3]

Generic launch scenarios

Scenario	Probability assessment	Commercial effect
Conventional 200 mg capsule generic	High technical feasibility	Price competition and substitution
Conventional 500 mg tablet generic	High technical feasibility	Limited differentiation
Novel lower-dose boosted formulation	Moderate technical complexity	Requires clinical and regulatory support
Pediatric liquid	Moderate technical complexity	Niche opportunity
Long-acting injectable	Low relevance to excipient-only strategy	Requires new delivery platform
Fixed-dose combination	Commercially difficult	Depends on regimen relevance and partner rights

A Paragraph IV challenge would have limited impact if no enforceable listed patents remain. The more important barrier is commercial demand. HIV treatment has shifted toward integrase inhibitor-based regimens, while protease-inhibitor use is concentrated in treatment-experienced patients, salvage therapy, or settings where alternatives are unsuitable.[2]

What is the Orange Book status of Invirase?

Invirase is regulated as an FDA-approved small-molecule product under NDA 020628. The Orange Book, rather than the biologics section of FDA’s reference-product framework, governs any listed patents and therapeutic-equivalence information for the product.[1][3]

No biosimilar pathway applies to saquinavir. A competitor would generally pursue:

• An ANDA for an equivalent capsule or tablet
• A 505(b)(2) application for a materially different formulation
• A full NDA if the product introduces substantial new clinical or therapeutic claims

A novel excipient combination with a clinically meaningful pharmacokinetic improvement is more likely to require a 505(b)(2) strategy than a simple ANDA, particularly if the dosage form, strength, food instructions, or exposure profile differs from the reference product.

How strong is the Invirase patent estate?

The legacy estate is commercially weak for new product development. The original active-ingredient and product claims are mature, and conventional excipient combinations are unlikely to support durable exclusivity.

Potentially stronger claim categories

A new developer could seek protection around:

1. A defined amorphous saquinavir dispersion with specified solid-state characteristics.
2. A lipid formulation producing a specified exposure profile.
3. A reduced-food-effect dosage form.
4. A stable pediatric suspension with a defined particle-size distribution.
5. A manufacturing process that prevents degradation or recrystallization.
6. A lower-dose regimen enabled by a reproducible pharmacokinetic gain.
7. A combination formulation that improves adherence or reduces pill burden.

The strongest patent position would combine composition claims with process and performance claims. A single excipient substitution, without a demonstrated technical effect, would be vulnerable to design-around and obviousness challenges.

Which companies are challenging or competing with Invirase?

The competitive threat does not come primarily from direct saquinavir generics. It comes from alternative antiretroviral classes and regimens.

Competitive landscape

• Integrase strand transfer inhibitor products, including dolutegravir- and bictegravir-based regimens, have become central to first-line HIV treatment.
• Boosted protease inhibitors such as darunavir-based products compete in treatment-experienced populations.
• Generic antiretroviral manufacturers can supply lower-cost alternatives across established classes.
• Specialty HIV manufacturers may pursue liquid, pediatric, or adherence-focused dosage forms rather than conventional saquinavir tablets.

The strongest commercial position for a new saquinavir formulation would therefore be a narrow clinical segment with a documented need, not broad first-line HIV use.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers have a more credible opportunity in enabling technology than in supplying the existing Invirase excipients.

High-value opportunity areas

Solubility-enhancing excipients

Polymeric precipitation inhibitors, surfactants, and lipid excipients could support a reformulation program. Commercial value depends on whether the supplier can provide regulatory history, global compendial status, and scale-up data.

Direct-compression and high-load systems

A high-drug-load formulation could reduce tablet size or manufacturing cost. Co-processed excipients may improve flow, content uniformity, and compression while maintaining rapid disintegration.

Pediatric excipient systems

A ready-to-use suspension or dispersible granule could create a differentiated product. The formulation must avoid unnecessary ethanol, excessive sugar, problematic preservatives, and excipients with poor chronic-use acceptability.

Continuous manufacturing

A robust powder-processing platform could reduce batch variability in a high-dose tablet. Process control would be more commercially defensible if tied to dissolution, solid-state stability, and content uniformity.

What licensing deals and partnerships are realistic?

A direct license to the legacy Invirase brand would have limited value unless it includes a broader commercial right or a new clinical development program. More viable structures include:

• Excipient supplier licensing a solubility-enhancement platform to a generic manufacturer.
• Contract development and manufacturing of a pediatric or specialty formulation.
• 505(b)(2) collaboration with a company holding HIV commercial infrastructure.
• Regional licensing in markets where protease-inhibitor use remains higher.
• Co-development of a fixed-dose or adherence-oriented product.

Roche’s historical rights and the current status of any regional commercialization arrangements must be separated from ownership of a new formulation patent. A new developer should not assume that legacy brand ownership provides freedom to operate for a reformulated product.

What manufacturing and geographic barriers apply?

The active ingredient is old, but formulation execution can still create practical barriers. Key manufacturing issues include:

• Control of saquinavir particle size and solid form
• Prevention of amorphous-to-crystalline conversion
• Uniform distribution at high drug loading
• Compatibility with capsule shells and coating systems
• Control of residual solvents in lipid or polymer formulations
• Stability under humid and hot-climate conditions
• Supply continuity for specialized polymers or surfactants

Geographically, commercial demand is likely to be more price-sensitive in lower- and middle-income markets. A novel formulation must justify its added cost through a clear benefit, such as reduced dose, lower food dependence, improved pediatric usability, or fewer dosing errors.

What revenue exposure does Invirase create for a new formulation developer?

The revenue opportunity is likely niche rather than mass-market. The addressable segments are:

• Patients unable to tolerate or access newer antiretroviral classes
• Treatment-experienced patients requiring a protease inhibitor
• Pediatric patients needing flexible dosing
• Markets where existing saquinavir supply is inconsistent
• Hospitals requiring an alternative oral formulation
• Public-sector procurement programs seeking lower-cost manufacturing

A conventional generic tablet would face rapid price erosion and limited prescribing growth. A differentiated formulation could support better margins, but the development program would need clinical evidence and a targeted commercial strategy.

Key Takeaways

• Invirase is saquinavir mesylate, an older small-molecule HIV protease inhibitor used with ritonavir.
• Its principal formulation problems are poor solubility, variable exposure, extensive metabolism, and food dependence.
• Existing capsule and tablet excipients are conventional and provide little standalone patent differentiation.
• The strongest excipient strategies are amorphous solid dispersions, lipid systems, nanocrystals, pediatric liquids, and multiparticulate products.
• Invirase has no biosimilar risk; competition would arise through ANDA or 505(b)(2) products.
• The original patent and exclusivity position is mature, making conventional generic entry technically feasible.
• Commercial opportunity is concentrated in specialty, pediatric, regional, and treatment-experienced markets.
• A defensible new patent estate would require a defined formulation, manufacturing process, or pharmacokinetic benefit.
• Excipient suppliers have a stronger opportunity in enabling technologies than in supplying the legacy formulation ingredients.

FAQs

Can saquinavir be reformulated as an amorphous solid dispersion?

Yes. An amorphous solid dispersion is technically plausible for improving dissolution, but it would require control of recrystallization, moisture sensitivity, drug loading, and long-term stability.

Is Invirase suitable for a pediatric oral suspension?

Potentially. A pediatric product would need taste masking, dose flexibility, acceptable chronic-use excipients, microbiological control, and an appropriate regulatory pathway.

Would a new Invirase formulation qualify for patent protection?

Possibly, if the formulation has a specific composition and a non-obvious technical effect, such as improved exposure, reduced food dependence, enhanced stability, or reduced dose.

Are excipients in Invirase themselves protected by patents?

The conventional excipients identified in the FDA label are widely used pharmaceutical ingredients. Protection would more likely depend on a specific formulation combination, process, or performance limitation than on the individual excipients.

Would a generic Invirase product be a biosimilar?

No. Saquinavir is a small molecule. A competing product would generally use the ANDA pathway for pharmaceutical equivalence or a 505(b)(2) pathway for a materially different formulation.

References

1. U.S. Food and Drug Administration. (2010). Invirase (saquinavir mesylate) capsules and tablets: Prescribing information. FDA.

2. U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. National Institutes of Health.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.